204 related articles for article (PubMed ID: 20147779)
1. The role of chemokine receptor CXCR4 in lung cancer.
Gangadhar T; Nandi S; Salgia R
Cancer Biol Ther; 2010 Mar; 9(6):409-16. PubMed ID: 20147779
[TBL] [Abstract][Full Text] [Related]
2. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential.
Wald O; Shapira OM; Izhar U
Theranostics; 2013; 3(1):26-33. PubMed ID: 23382783
[TBL] [Abstract][Full Text] [Related]
3. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
[TBL] [Abstract][Full Text] [Related]
4. The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer.
Hartmann TN; Burger M; Burger JA
J Biol Regul Homeost Agents; 2004; 18(2):126-30. PubMed ID: 15471215
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 chemokine receptor antagonists: perspectives in SCLC.
Burger JA; Stewart DJ
Expert Opin Investig Drugs; 2009 Apr; 18(4):481-90. PubMed ID: 19335276
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
Hartmann TN; Burger JA; Glodek A; Fujii N; Burger M
Oncogene; 2005 Jun; 24(27):4462-71. PubMed ID: 15806155
[TBL] [Abstract][Full Text] [Related]
7. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer.
Otsuka S; Bebb G
J Thorac Oncol; 2008 Dec; 3(12):1379-83. PubMed ID: 19057260
[TBL] [Abstract][Full Text] [Related]
8. Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.
Katsura M; Shoji F; Okamoto T; Shimamatsu S; Hirai F; Toyokawa G; Morodomi Y; Tagawa T; Oda Y; Maehara Y
Cancer Sci; 2018 Jan; 109(1):154-165. PubMed ID: 29032612
[TBL] [Abstract][Full Text] [Related]
9. CXCR4/CXCL12 in non-small-cell lung cancer metastasis to the brain.
Cavallaro S
Int J Mol Sci; 2013 Jan; 14(1):1713-27. PubMed ID: 23322021
[TBL] [Abstract][Full Text] [Related]
10. The role of the CXCR4/CXCL12 axis and its clinical implications in gastric cancer.
Lee HJ; Jo DY
Histol Histopathol; 2012 Sep; 27(9):1155-61. PubMed ID: 22806902
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.
Zhang C; Li J; Han Y; Jiang J
Drug Des Devel Ther; 2015; 9():3267-78. PubMed ID: 26150700
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.
Jung MJ; Rho JK; Kim YM; Jung JE; Jin YB; Ko YG; Lee JS; Lee SJ; Lee JC; Park MJ
Oncogene; 2013 Jan; 32(2):209-21. PubMed ID: 22370645
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.
Wang Z; Sun J; Feng Y; Tian X; Wang B; Zhou Y
Tumour Biol; 2016 Jul; 37(7):8515-28. PubMed ID: 27079871
[TBL] [Abstract][Full Text] [Related]
14. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
15. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.
Burger M; Glodek A; Hartmann T; Schmitt-Gräff A; Silberstein LE; Fujii N; Kipps TJ; Burger JA
Oncogene; 2003 Nov; 22(50):8093-101. PubMed ID: 14603250
[TBL] [Abstract][Full Text] [Related]
16. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer.
Pfeiffer M; Hartmann TN; Leick M; Catusse J; Schmitt-Graeff A; Burger M
Br J Cancer; 2009 Jun; 100(12):1949-56. PubMed ID: 19455144
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
19. Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016.
Otani Y; Kijima T; Kohmo S; Oishi S; Minami T; Nagatomo I; Takahashi R; Hirata H; Suzuki M; Inoue K; Takeda Y; Kida H; Tachibana I; Fujii N; Kumanogoh A
FEBS Lett; 2012 Oct; 586(20):3639-44. PubMed ID: 22992418
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.
Stumpf C; Kaemmerer D; Neubauer E; Sänger J; Schulz S; Lupp A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1921-1932. PubMed ID: 30076481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
